Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2032

Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2032

DelveInsight’s ‘Idiopathic Membranous Nephropathy (IMN) Overview – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the Idiopathic Membranous Nephropathy (IMN), historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy (IMN) epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Idiopathic Membranous Nephropathy (IMN) Understanding

Idiopathic Membranous Nephropathy (IMN) Overview

Membranous Nephropathy (MN) is a kidney disease that affects the filters of the kidney. It causes protein increase in urine, abnormal kidney function, and swelling. It is also called membranous glomerulopathy. MN is a rare disease affecting the kidney glomerulus, specifically the podocytes, which are key in controlling the kidney’s permeability to proteins. Albumin and higher molecular weight proteins are minimally filtered in a healthy individual. In contrast, in nephrotic syndrome, large amounts of proteins escape into the urine, decreasing serum albumin and developing generalized edema.

Primary MN is when the disease is associated serologically with antibodies to a known antigen, such as the M-type phospholipase A2 receptor (PLA2R) or thrombospondin type-I domain-containing 7A (THSD7A). In about 70–80% of cases with primary MN, an antibody called anti-PLA2R is found in the kidney and bloodstream.

Secondary MN is identified when the lesion of MN can be associated with other systemic illnesses or exposures like infection, autoimmune disease, NSAIDs, cancer, etc.

Continued in the report…

Idiopathic Membranous Nephropathy (IMN) Diagnosis

The diagnosis of IMN is often diagnosed by evaluating protein in the urine (normally, there should not be protein in the urine). Others go to the doctor because of symptoms such as swelling, and blood and urine examinations reveal protein in the urine. The doctor may suggest examinations like urine tests, blood tests, etc. A blood test will help find protein, cholesterol, and waste levels in the blood. A kidney biopsy is a gold standard in confirming the diagnosis. In this test, a tiny kidney is removed with a special needle and looked at under a microscope. The kidney biopsy may show if you have a certain type of protein that helps the body fight infection, called an antibody. The body usually makes this antibody when you have MN. It is used either exclusively or in combination with antibody assay.

While the diagnosis of primary MN requires a kidney biopsy, recently, the availability of assays for PLA2R antibodies has dramatically changed the diagnostic strategy, owing to the very high specificity (99%) of anti-PLA2R antibodies for the diagnosis of MN.

Continued in the report…

Idiopathic Membranous Nephropathy (IMN) Epidemiology Perspective by DelveInsight

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Idiopathic Membranous Nephropathy (IMN), Prevalence of Idiopathic Membranous Nephropathy (IMN) by Antigens covering the United States, the EU4 (Germany, France, Italy, Spain), UK and Japan from 2019 to 2032.

Key Findings

In 2022, among the 7MM, the United States accounted for the highest proportion (~41%) of prevalent cases of IMN.

EU4 and the UK accounted for ~24,000 cases of IMN in 2022, which is expected to increase by 2032.

In 2022, Japan accounted for ~23% of the total prevalent IMN cases among the 7MM countries. Approximately 16,000 IMN cases were observed in Japan in 2022.

Among EU4 and the UK, France had the lowest number of prevalent cases of IMN at ~4,100 cases in 2022. As per DelveInsight’s estimates, these cases are expected to increase by 2032.

Approximately one-third of participants with IMN undergo spontaneous remission. In 2022, the addressable pool of IMN included ~47,000 cases in the 7MM.

About 80% of MN cases are renal limited (primary MN), and 20% are associated with other systemic diseases or exposures (secondary MN).

In the United States, PLA2R and THSD7A antigens were observed in ~80% and ~3% of IMN patients, respectively.

Scope of the Report

The report covers a descriptive overview of Idiopathic Membranous Nephropathy (IMN), explaining its causes, symptoms, and diagnosis.

The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The report assesses the Idiopathic Membranous Nephropathy (IMN) risks and burdens.

The report provides the segmentation of the epidemiology for 7MM segmented by ‘Prevalence of Idiopathic Membranous Nephropathy (IMN), Prevalence of Idiopathic Membranous Nephropathy (IMN) by Antigens.’

Report Highlights

10-year Forecast of Idiopathic Membranous Nephropathy (IMN)

7MM Coverage

Prevalence of Idiopathic Membranous Nephropathy (IMN)

Prevalence of Idiopathic Membranous Nephropathy (IMN) by Antigens

Key Questions Answered

What are the risk and burdens of Idiopathic Membranous Nephropathy (IMN)?

What is the historical Idiopathic Membranous Nephropathy (IMN) patient pool in the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan?

What would be the forecasted patient pool of Idiopathic Membranous Nephropathy (IMN) at the 7MM level?

What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Idiopathic Membranous Nephropathy (IMN)?

Out of the countries mentioned above, which country would have the highest cases of Idiopathic Membranous Nephropathy (IMN) during the forecast period (2023–2032)?

At what CAGR is the population expected to grow across the 7MM during the forecast period (2023–2032)?

Reasons to buy

The Idiopathic Membranous Nephropathy (IMN) report will allow the user to -

Develop business strategies by understanding the trends, shaping and driving the 7MM Idiopathic Membranous Nephropathy (IMN) epidemiology.

The Idiopathic Membranous Nephropathy (IMN) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.

The Idiopathic Membranous Nephropathy (IMN) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Geographies Covered

The United States

EU4 (Germany, France, Italy, Spain) and the United Kingdom

Japan

Study Period: 2019–2032